EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder

Amanda Gollo Bertollo iD, Ricieri Mocelin iD, Zuleide Maria Ignácio iD

Pharmaceuticals · 11.09.2025 · 18 (9) · 1360

DOI: 10.3390/ph18091360 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 11.09.2025. Verfasst von Amanda Gollo Bertollo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Neurosciences, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, UFFS, FAPESC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Genetic polymorphisms within specific genes play a role in both the genetic predisposition to Major Depressive Disorder (MDD) and the variation observed in responses to antidepressant treatments. Pharmacogenetics examines how these polymorphisms affect medication response. This review highlights significant disparities in the pharmacogenetic influences on antidepressant response, with a focus on ethnic and sex-based differences.

Methods

This review synthesizes findings from a comprehensive literature search conducted between 2000 and 2025. It utilized databases such as PubMed, Scopus, and Web of Science, using search terms including “pharmacogenetics”, “antidepressants”, “Major Depressive Disorder”, “CYP450”, “neuroplasticity”, and “genetic variations”. This review integrates pharmacogenetics with neurotransmitters and their transporters, neuroplasticity, growth factors, and the cytochrome P450 family, providing promising insights for personalized MDD treatment strategies. We analyzed and synthesized findings from over 50 relevant studies, focusing on those with a clear emphasis on genetic associations with antidepressant efficacy and adverse effects.

Results

Pharmacogenetic analysis facilitates personalized antidepressant prescriptions by identifying key genetic variants that influence treatment outcomes. Specifically, variations in CYP2D6 and CYP2C19 can significantly impact drug metabolism and tolerability. A high percentage of patients with non-normal metabolizer phenotypes are predisposed to adverse drug reactions or ineffective responses. Furthermore, this review identifies significant ethnic and sex-based disparities in treatment response. For example, the L allele of the 5-HTTLPR polymorphism confers a higher likelihood of response and remission following SSRI treatment in white people compared to Asians. Additionally, in women, specific 5-HTTLPR polymorphisms have a more pronounced influence on mood and MDD pathophysiology, with a significant reduction in mood in response to tryptophan depletion.

Conclusions

Integrating pharmacogenetic insights, encompassing genetic factors, neurotransmitter pathways, neuroplasticity, and the influence of ethnicity and sex, is crucial for developing personalized antidepressant treatment strategies. This will ultimately optimize patient recovery and minimize adverse effects.

Schlagwörter

Stichwörter der Autor:innen

antidepressantsgenetic variationsmajor depressive disorderpersonalized medicinepharmacogenetics

Autor:innen und Institutionen

  • Graduate Program in Neurosciences, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil.
  • Laboratory of Physiology, Pharmacology, and Psychopathology, Graduate Program in Biomedical Sciences, Federal University of Fronteira Sul, Chapecó 89815-899, SC, Brazil.
  • Translational Neuropsychobiology Laboratory, Graduate Program in Biomedical Sciences, Federal University of Fronteira Sul, Passo Fundo 99010-020, RS, Brazil.

ORCID-Profile: Amanda Gollo Bertollo, Ricieri Mocelin, Zuleide Maria Ignácio

Förderung

  • NCATS NIH HHS
  • UFFS
  • FAPESC

Zitieren

APA

Bertollo, A. G., Mocelin, R., & Ignácio, Z. M. (2025). Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder. Pharmaceuticals, 18(9), 1360. https://doi.org/10.3390/ph18091360

Vancouver

Bertollo AG, Mocelin R, Ignácio ZM. Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder. Pharmaceuticals. 2025;18(9):1360. doi:10.3390/ph18091360

BibTeX
@article{Bertollo2025,
  author = {Bertollo, Amanda Gollo and Mocelin, Ricieri and Ignácio, Zuleide Maria},
  title = {Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {9},
  pages = {1360},
  doi = {10.3390/ph18091360}
}
Kostenlos starten →